Filtros de búsqueda

Lista de obras de Alessandro Morabito

A complete atrioventricular block secondary to myocardial metastases of lung cancer. A case report.

artículo científico publicado en 2005

A multicenter, randomized, phase 3 trial comparing fixed dose versus toxicity-adjusted dose of cisplatin + etoposide in extensive small-cell lung cancer (SCLC) patients: The Small-cell-lung cancer Toxicity Adjusted Dosing (STAD-1) trial

artículo científico publicado en 2017

A new look at the ALK gene in cancer: copy number gain and amplification

artículo científico publicado en 2016

A phase I study of paclitaxel and epirubicin, without and with filgrastim, for the treatment of platinum-resistant advanced ovarian cancer

scientific article published on 01 January 1999

A phase I-II study of gemcitabine and docetaxel in advanced pancreatic cancer: a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD).

artículo científico publicado en 1999

A phase II study of capecitabine in the treatment of ovarian cancer resistant or refractory to platinum therapy: a multicentre Italian trial in ovarian cancer (MITO-6) trial.

artículo científico publicado en 2009

Activity of chemotherapy in mucinous ovarian cancer with a recurrence free interval of more than 6 months: results from the SOCRATES retrospective study.

artículo científico publicado en 2008

Activity of gefitinib in a non-small-cell lung cancer patient with both activating and resistance EGFR mutations

artículo científico publicado en 2013

Advanced non-small-cell lung cancer with epidermal growth factor receptor mutations: current evidence and future perspectives

artículo científico

Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial

artículo científico

Afatinib: An overview of its clinical development in non-small-cell lung cancer and other tumors

artículo científico

Anaplastic lymphoma kinase: a glimmer of hope in lung cancer treatment?

artículo científico

Angiogenesis Inhibitors in NSCLC.

artículo científico publicado en 2017

Angiogenesis sustains tumor dormancy in patients with breast cancer treated with adjuvant chemotherapy.

artículo científico publicado en 2001

Antiangiogenic strategies, compounds, and early clinical results in breast cancer

artículo científico publicado en 2004

Are tumor-infiltrating lymphocytes protagonists or background actors in patient selection for cancer immunotherapy?

artículo científico publicado en 2017

Assessment of high-sensitive methods for the detection of EGFR mutations in circulating free tumor DNA from NSCLC patients

artículo científico publicado en 2015

Association of ERBB Mutations With Clinical Outcomes of Afatinib- or Erlotinib-Treated Patients With Lung Squamous Cell Carcinoma: Secondary Analysis of the LUX-Lung 8 Randomized Clinical Trial

BE-POSITIVE: Beyond progression after tyrosine kinase inhibitor in EGFR- positive non small cell lung cancer patients: Results from a multicenter Italian observational study.

artículo científico publicado en 2016

BEVERLY: Rationale and Design of a Randomized Open-Label Phase III Trial Comparing Bevacizumab Plus Erlotinib Versus Erlotinib Alone as First-Line Treatment of Patients With EGFR-Mutated Advanced Nonsquamous Non-Small-Cell Lung Cancer

artículo científico publicado en 2016

Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression ≥ 50%: a multicenter study with external validation

scientific article published on 01 October 2020

Behaviour of metastasis in relation to vascular index in patients with node-positive breast cancer treated with adjuvant tamoxifen

artículo científico publicado en 2000

Biomarker analysis of the phase 3 TORCH trial for first line erlotinib versus chemotherapy in advanced non-small cell lung cancer patients

artículo científico publicado en 2017

Bone effect of adjuvant tamoxifen, letrozole or letrozole plus zoledronic acid in early-stage breast cancer: the randomized phase 3 HOBOE study

scientific article published on 12 March 2012

CD90 expression in atypical meningiomas and meningioma metastasis.

artículo científico

CMF vs alternating CMF/EV in the adjuvant treatment of operable breast cancer. A single centre randomised clinical trial (Naples GUN-3 study).

artículo científico publicado en 1995

Carboplatin and pegylated liposomal doxorubicin for advanced ovarian cancer: preliminary activity results of the MITO-2 phase III trial

artículo científico publicado en 2008

Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trial

artículo científico publicado en 2011

Ceritinib compassionate use for patients with crizotinib-refractory, anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer

artículo científico publicado en 2017

Cetuximab and gemcitabine in elderly or adult PS2 patients with advanced non-small-cell lung cancer: The cetuximab in advanced lung cancer (CALC1-E and CALC1-PS2) randomized phase II trials.

artículo científico publicado en 2010

Cetuximab in non-small-cell lung cancer

Cisplatin plus gemcitabine or vinorelbine for elderly patients with advanced non small-cell lung cancer: the MILES-2P studies

artículo científico publicado en 2007

Cisplatin versus carboplatin in combination with mitomycin and vinblastine in advanced non small cell lung cancer. A multicenter, randomized phase III trial.

artículo científico publicado en 2004

Cisplatin/Pemetrexed Followed by Maintenance Pemetrexed Versus Carboplatin/Paclitaxel/Bevacizumab Followed by Maintenance Bevacizumab in Advanced Nonsquamous Lung Cancer: The GOIM (Gruppo Oncologico Italia Meridionale) ERACLE Phase III Randomized Tr

artículo científico publicado en 2014

Clinical assessment of patients with advanced non-small-cell lung cancer eligible for second-line chemotherapy: a prognostic score from individual data of nine randomised trials

artículo científico publicado en 2010

Clinical benefit of intermittent administration of imatinib in a patient with metastatic gastrointestinal stromal tumour

artículo científico publicado en 2005

Clinical trials and drug cost savings for Italian health service

scientific article published on 26 November 2020

Clinical utility of circulating tumor cells in patients with non-small-cell lung cancer

artículo científico publicado en 2017

Combined therapy with weekly irinotecan, infusional 5-fluorouracil and the selective COX-2 inhibitor rofecoxib is a safe and effective second-line treatment in metastatic colorectal cancer

artículo científico publicado en 2005

Combining anti-Epidermal Growth Factor Receptor (EGFR) and anti-angiogenic strategies in advanced NSCLC: we should have known better….

artículo científico

Conditioned medium of primary lung cancer cells induces EMT in A549 lung cancer cell line by TGF-ß1 and miRNA21 cooperation

scientific article published on 25 July 2019

Correction: Intratumor Heterogeneity of ALK-Rearrangements and Homogeneity of EGFR-Mutations in Mixed Lung Adenocarcinoma

artículo científico publicado en 2015

Correlation of Serum Cystatin C with Glomerular Filtration Rate in Patients Receiving Platinum-Based Chemotherapy.

artículo científico publicado en 2016

Costs of clinical trials with anticancer biological agents in an Oncologic Italian Cancer Center using the activity-based costing methodology

artículo científico publicado en 2019

Crizotinib Response in a Late Relapse of ALK-positive Lung Adenocarcinoma

artículo científico publicado en 2016

Dacomitinib compared with placebo in pretreated patients with advanced or metastatic non-small-cell lung cancer (NCIC CTG BR.26): a double-blind, randomised, phase 3 trial

artículo científico publicado en 2014

Detection of EGFR mutations by TaqMan mutation detection assays powered by competitive allele-specific TaqMan PCR technology

artículo científico publicado en 2013

Diagnosis of anaplastic lymphoma kinase rearrangement in cytological samples through a fluorescence in situ hybridization-based assay: Cytological smears versus cell blocks

artículo científico publicado en 2017

Doxorubicin-docetaxel sequential schedule: results of front-line treatment in advanced breast cancer

artículo científico publicado en 2002

EGFR mutations in lung cancer: from tissue testing to liquid biopsy

artículo científico

Effects on quality of life of weekly docetaxel-based chemotherapy in patients with locally advanced or metastatic breast cancer: results of a single-centre randomized phase 3 trial

artículo científico publicado en 2011

Efficacy and safety of rechallenge treatment with gefitinib in patients with advanced non-small cell lung cancer.

artículo científico publicado en 2016

Endocrine effects of adjuvant letrozole + triptorelin compared with tamoxifen + triptorelin in premenopausal patients with early breast cancer

artículo científico publicado en 2007

Endocrine effects of adjuvant letrozole compared with tamoxifen in hormone-responsive postmenopausal patients with early breast cancer: the HOBOE trial

artículo científico publicado en 2009

Evaluation of the VeriStrat® serum protein test in patients with advanced squamous cell carcinoma of the lung treated with second-line afatinib or erlotinib in the phase III LUX-Lung 8 study

artículo científico publicado en 2017

Factorial phase III randomised trial of rofecoxib and prolonged constant infusion of gemcitabine in advanced non-small-cell lung cancer: the GEmcitabine-COxib in NSCLC (GECO) study

artículo científico publicado en 2007

Failure of a cetuximab/bevacizumab schedule in a patient with metastatic desmoplastic small round-cell tumour refractory to chemotherapy.

artículo científico publicado en 2005

First-line chemotherapy for HER-2 negative metastatic breast cancer patients who received anthracyclines as adjuvant treatment

artículo científico publicado en 2007

First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non-small-cell lung cancer: the TORCH randomized trial

artículo científico publicado en 2012

Focus on Nintedanib in NSCLC and Other Tumors

artículo científico publicado en 2016

Gefitinib in non small cell lung cancer

artículo científico publicado en 2011

High-dose recombinant interleukin-2/verapamil combination in advanced cancer

artículo científico publicado en 1996

Hormonal treatment of human hepatocellular carcinoma.

artículo científico publicado en 2006

Immunotherapy in Small Cell Lung Cancer

artículo científico publicado en 2020

Impact of COVID-19 outbreak on cancer immunotherapy in Italy: a survey of young oncologists

scientific article published on 01 October 2020

Induction Therapy for Lung Cancer: Sailing Across the Pillars of Hercules ⬇️

artículo científico publicado el 12 de octubre de 2011

Inhibitors of cyclo-oxygenase 2: a new class of anticancer agents?

artículo científico publicado en 2003

Integrated therapeutic approaches in the treatment of locally advanced non-small cell lung cancer

artículo científico publicado en 2013

Interleukin-2-induced renal dysfunction in cancer patients is reversed by low-dose dopamine infusion

artículo científico publicado en 1995

Intratumor Heterogeneity of ALK-Rearrangements and Homogeneity of EGFR-Mutations in Mixed Lung Adenocarcinoma

artículo científico publicado en 2015

Is epirubicin effective in first-line chemotherapy of metastatic breast cancer (MBC) after an epirubicin-containing adjuvant treatment? A single centre phase III trial.

artículo científico publicado en 2006

Is human hepatocellular carcinoma a hormone-responsive tumor?

artículo científico publicado en 2008

Is tailored therapy feasible in oncology?

artículo científico publicado en 2005

Limits and potential of targeted sequencing analysis of liquid biopsy in patients with lung and colon carcinoma.

scientific article published on 19 July 2016

Low-dose dopamine induces early recovery of recombinant interleukin-2--impaired renal function

scientific article published on 01 January 1993

Lungs on Fire

artículo científico publicado en 2015

Meta-analysis of single-agent chemotherapy compared with combination chemotherapy as second-line treatment of advanced non-small-cell lung cancer

artículo científico publicado en 2009

Methodological aspects of lung cancer clinical trials in the era of targeted agents

artículo científico publicado en 2009

Metronomic administration of zoledronic acid and taxotere combination in castration resistant prostate cancer patients: phase I ZANTE trial

artículo científico publicado en 2010

Multiorganic dissemination of a colorectal signet ring cell carcinoma with fulminant clinical course.

artículo científico publicado en 2006

Multiple effectiveness aspects of tapentadol for moderate-severe cancer-pain treatment: an observational prospective study

artículo científico publicado en 2018

New drugs in advanced non-small-cell lung cancer: searching for the correct clinical development

artículo científico publicado en 2010

Next Generation Sequencing-Based Profiling of Cell Free DNA in Patients with Advanced Non-Small Cell Lung Cancer: Advantages and Pitfalls

artículo científico publicado en 2020

Optimizing response to gefitinib in the treatment of non-small-cell lung cancer

artículo científico publicado en 2011

Pembrolizumab in lung cancer: current evidence and future perspectives

scientific article published on 21 August 2019

Phase I-II Trial of Gemcitabine-Based First-Line Chemotherapies for Small Cell Lung Cancer in Elderly Patients with Performance Status 0-2: The G-Step Trial ⬇️

artículo científico publicado el 1 de enero de 2012

Poor outcome of elderly patients with platinum-sensitive recurrent ovarian cancer: results from the SOCRATES retrospective study.

artículo científico publicado en 2009

Positron emission tomography and circulating tumor cells to monitor a dramatic response to gefitinib.

artículo científico publicado en 2012

Pretreatment quality of life and functional status assessment significantly predict survival of elderly patients with advanced non-small-cell lung cancer receiving chemotherapy: a prognostic analysis of the multicenter Italian lung cancer in the eld

artículo científico publicado en 2005

Prognostic and predictive indicators in operable breast cancer

artículo científico publicado en 2003

Prognostic impact of education level of patients with advanced non-small cell lung cancer enrolled in clinical trials

artículo científico publicado en 2012

Prognostic significance of necrosis, elastosis, fibrosis and inflammatory cell reaction in operable breast cancer

artículo científico publicado en 1995

Prognostic value of circulating tumor cells' reduction in patients with extensive small-cell lung cancer

artículo científico publicado en 2014

Prolonged control of bone metastases in non-small-cell lung cancer patients treated with gefitinib

artículo científico publicado en 2008

Quality of life analysis of TORCH, a randomized trial testing first-line erlotinib followed by second-line cisplatin/gemcitabine chemotherapy in advanced non-small-cell lung cancer

artículo científico publicado en 2012

Randomized Phase II Trial of weekly paclitaxel alone versus trastuzumab plus weekly paclitaxel as first-line therapy of patients with Her-2 positive advanced breast cancer

artículo científico publicado en 2006

Randomized phase III trial of gemcitabine and cisplatin vs. gemcitabine alone in patients with advanced non-small cell lung cancer and a performance status of 2: the CAPPA-2 study

artículo científico publicado en 2013

Rationale and design of MILES-3 and MILES-4 studies: two randomized phase 3 trials comparing single-agent chemotherapy versus cisplatin-based doublets in elderly patients with advanced non--small-cell lung cancer

artículo científico publicado en 2013

Safety and activity of the combination of pegylated liposomal doxorubicin and weekly docetaxel in advanced breast cancer.

artículo científico publicado en 2004

Safety and efficacy of buparlisib (BKM120) and chemotherapy in advanced, squamous non-small cell lung cancer (sqNSCLC): Results from the phase Ib/II BASALT-2 and BASALT-3 studies

Second-line treatment for advanced NSCLC without actionable mutations: is immunotherapy the 'panacea' for all patients?

artículo científico publicado en 2018

Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: final analysis of the GioTag study

scientific article published on 28 August 2020

Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: updated analysis of the observational GioTag study

artículo científico publicado en 2019

Sequential treatment with afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: an observational study

artículo científico publicado en 2018

Survival After Surgical Treatment of Lung Cancer Arising in the Population Exposed to Illegal Dumping of Toxic Waste in the Land of Fires ('Terra dei Fuochi') of Southern Italy

artículo científico publicado en 2016

Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting in three randomized trials

artículo científico publicado en 2015

Systemic treatment of gastric cancer

artículo científico publicado en 2008

Target-based therapies in breast cancer: current status and future perspectives.

scientific article published on 12 June 2009

Thalidomide is inactive in heavily pretreated patients with metastatic breast cancer

artículo científico publicado en 2005

Thalidomide prolongs disease stabilization after conventional therapy in patients with recurrent glioblastoma.

artículo científico publicado en 2004

The MILES-2G phase 2 study of single-agent gemcitabine with prolonged constant infusion in advanced non-small cell lung cancer elderly patients

artículo científico publicado en 2008

The combination of gemcitabine and vinorelbine is an active regimen as second-line therapy in patients with metastatic breast cancer pretreated with taxanes and/or anthracyclines: a phase I-II study

artículo científico publicado en 2003

The evolution of the treatment of advanced NSCLC.

artículo científico publicado en 2016

The role of immunotherapy in solid tumors: report from the Campania Society of Oncology Immunotherapy (SCITO) meeting, Naples 2014

artículo científico publicado en 2014

Therapy of breast cancer with molecular targeting agents.

artículo científico publicado en 2005

Thrombospondin-1 and -2 in node-negative breast cancer: correlation with angiogenic factors, p53, cathepsin D, hormone receptors and prognosis

artículo científico publicado en 2001

Time spent for activation of non-profit studies in oncology in Italy

artículo científico publicado en 2010

Trastuzumab beyond progression: is the risk of cardiac toxicity really not increased?

artículo científico publicado en 2009

Trastuzumab in combination with gemcitabine and vinorelbine as second-line therapy for HER-2/neu overexpressing metastatic breast cancer

artículo científico publicado en 2006

Treatment of pulmonary neuroendocrine tumours: state of the art and future developments

artículo científico

Treatment of small cell lung cancer

scholarly article by Alessandro Morabito et al published September 2014 in Critical Reviews in Oncology Hematology

Tyrosine kinase inhibitors of vascular endothelial growth factor receptors in clinical trials: current status and future directions.

artículo científico publicado en 2006

Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: current status and future directions.

scientific article published on 06 April 2009

Vandetanib as a potential treatment for breast cancer.

artículo científico

Vandetanib: An overview of its clinical development in NSCLC and other tumors.

artículo científico publicado en 2010

Vinorelbine for non-small cell lung cancer.

artículo científico publicado en 2010

Vinorelbine plus 3-weekly trastuzumab in metastatic breast cancer: a single-centre phase 2 trial

artículo científico publicado en 2007

Weekly docetaxel versus CMF as adjuvant chemotherapy for elderly breast cancer patients: safety data from the multicentre phase 3 randomised ELDA trial

artículo científico publicado en 2007

Weekly docetaxel vs. docetaxel-based combination chemotherapy as second-line treatment of advanced non-small-cell lung cancer patients. The DISTAL-2 randomized trial

artículo científico publicado en 2008

ZEPHYR: failure of a "spring wind" in lung cancer

artículo científico publicado en 2013

ctDNA Determination of EGFR Mutation Status in European and Japanese Patients with Advanced NSCLC: The ASSESS Study

artículo científico publicado en 2016

Dominio Público Uruguay está sostenido por:

Acerca de Dominio Público Uruguay

Ayuda